Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site

Anne Kirstine Hundahl Møller, Karen Damgaard Pedersen, Julie Rafn Abildgaard, Bodil Laub Petersen, Gedske Daugaard

12 Citationer (Scopus)

Abstract

Treatment of patients with carcinoma of unknown primary site (CUP) remains a challenge, and no effective second-line treatment has been identified. In CUP patients who are non-responsive or relapse early after first-line platinum/taxane-based regimens, it is likely that gastrointestinal (GI) tract tumours may be overrepresented. These patients could be candidates for GI tract-directed therapy. We here report the results obtained with oxaliplatin and capecitabine as second-line therapy in 25 recurrent/refractory CUP patients following first-line treatment with paclitaxel, cisplatin and gemcitabine.
OriginalsprogEngelsk
TidsskriftActa Odontologica Scandinavica
Vol/bind49
Udgave nummer4
Sider (fra-til)431-5
Antal sider5
ISSN0001-6357
DOI
StatusUdgivet - 1 maj 2010

Fingeraftryk

Dyk ned i forskningsemnerne om 'Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site'. Sammen danner de et unikt fingeraftryk.

Citationsformater